BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yen YH, Kuo FY, Chen CH, Hu TH, Lu SN, Wang JH, Hung CH. Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice. Medicine (Baltimore) 2019;98:e16270. [PMID: 31277150 DOI: 10.1097/MD.0000000000016270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Grimm J, Peschel G, Müller M, Schacherer D, Wiest R, Weigand K, Buechler C. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J Clin Med 2021;10:1621. [PMID: 33920491 DOI: 10.3390/jcm10081621] [Reference Citation Analysis]
2 Weigand K, Peschel G, Grimm J, Luu K, Schacherer D, Wiest R, Müller M, Schwarz H, Buechler C. Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology. Eur J Immunol 2021. [PMID: 34914098 DOI: 10.1002/eji.202149488] [Reference Citation Analysis]
3 Pipe SW, Reddy KR, Chowdary P. Gene therapy: Practical aspects of implementation. Haemophilia 2022;28 Suppl 4:44-52. [PMID: 35521727 DOI: 10.1111/hae.14545] [Reference Citation Analysis]
4 Torgersen J, Taddei TH, Lo Re V. Reply to: “Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?”. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.025] [Reference Citation Analysis]